Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. by Mukhopadhyay, P. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Cannabidiol protects against hepatic ischemia/reperfusion injury 
by attenuating inflammatory signaling and response, 
oxidative/nitrative stress, and cell death. 
Authors: Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, 
Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, Haskó G, Mechoulam 
R, Pacher P 
Journal: Free radical biology &amp; medicine 
Year: 2011 May 15 
Volume: 50 
Issue: 10 
Pages: 1368-81 
DOI: 10.1016/j.freeradbiomed.2011.02.021 
 
Cannabidiol protects against hepatic ischemia/reperfusion injury
by attenuating inflammatory signaling and response, oxidative/
nitrative stress, and cell death
Partha Mukhopadhyay1,*, Mohanraj Rajesh1,*, Béla Horváth1,*, Sándor Bátkai1,*, Ogyi Park2,
Galin Tanashian1, Rachel Y Gao1, Vivek Patel1, David A. Wink3, Lucas Liaudet4, György
Haskó5, Raphael Mechoulam6, and Pál Pacher1
1 Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National
Institutes of Health, Bethesda, Maryland, USA 2 Laboratory of Liver Diseases, National Institute
on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA 3
Radiation Biology Branch, NCI, National Institutes of Health, Bethesda, Maryland, USA 4
Department of Intensive Care Medicine, University Hospital, Lausanne, Switzerland 5 Department
of Surgery, University of Medicine and Dentistry of New Jersey-New Jersey Medical School,
Newark, New Jersey 07103, USA 6 Department for Medicinal Chemistry and Natural Products,
Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel
Abstract
Ischemia-reperfusion (I/R) is a pivotal mechanism of liver damage following liver transplantation
or hepatic surgery. We have investigated the effects of cannabidiol(CBD), the non-psychotropic
constituent of marijuana, in a mouse model of hepatic I/R injury. I/R triggered time-dependent
increases/changes in markers of liver injury (serum transaminases), hepatic oxidative/nitrative
stress (4-hydroxy-2-nonenal, nitrotyrosine content/staining, gp91phox and inducible nitric oxide
synthase mRNA), mitochondrial dysfunction (decreased complex I activity), inflammation (tumor
necrosis factor alpha (TNF-α), cyclooxygenase 2, macrophage inflammatory protein-1α/2, inter-
cellular adhesion molecule 1 mRNA levels, tissue neutrophil infiltration, nuclear factor kappa B
(NF-KB) activation), stress signaling (p38MAPK and JNK) and cell death (DNA fragmentation,
PARP activity, and TUNEL). CBD significantly reduced the extent of liver inflammation,
oxidative/nitrative stress and cell death, and also attenuated the bacterial endotoxin-triggered NF-
KB activation and TNF-α production in isolated Kupffer cells, likewise the adhesion molecules
expression in primary human liver sinusoidal endothelial cells stimulated with TNF-α, and
attachment of human neutrophils to the activated endothelium. These protective effects were
preserved in CB2 knockout mice and were not prevented by CB1/2 antagonists in vitro. Thus, CBD
may represent a novel, protective strategy against I/R injury by attenuating key inflammatory
pathways and oxidative/nitrative tissue injury, independent from classical CB1/2 receptors.
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Introduction
Ischemia reperfusion (I/R) is the pivotal mechanism of tissue damage in pathological
conditions such as stroke, myocardial infarction, vascular surgery, organ transplantation, and
various forms of shock [1–4]. The destructive effects of I/R is triggered by the acute
generation of reactive oxygen and nitrogen species following reoxygenation, which causes
direct tissue injury and initiate a chain of deleterious cellular responses leading to
inflammation, cell death, which eventually culminate in target organ failure [3–12].
Cannabidiol (CBD) is the most abundant non-psychotropic constituent of Cannabis sativa
(marijuana) plant [13,14]. CBD has been reported to exert protective effects in multiple
disease models [13,15] and may alleviate pain and spasticity associated with multiple
sclerosis in humans [16]. In contrast to the delta 9-tetrahydrocannabinol (THC; the most
characterized active ingredient of marijuana) [14], CBD does not bind to classic cannabinoid
1 (CB1) receptors [17,18], which mediate the psychoactive and analgesic properties of
marijuana and THC in the central nervous system. Furthermore, CBD is also devoid of
potential to cause adverse cardiac effects mediated by cardiovascular CB1 receptors [19],
which have recently been implicated in the pathophysiology of multiple cardiovascular
diseases including heart failure, shock and atherosclerosis [19–21]. CBD is well tolerated
without side effects when chronically administered to humans [22,23] and has been
approved for the treatment of inflammation, pain and spasticity associated with multiple
sclerosis since 2005 in Canada [16,19]. Previous studies have suggested multiple
mechanisms to explain the beneficial effects of CBD in preclinical models of inflammation
and tissue injury [13], including its potent antioxidant [24] and anti-inflammatory [15,25]
properties.
In this study we have investigated the effects of CBD using an in vivo well characterized
mouse model of hepatic I/R injury [26–29] (in which the initial damage is inflicted by the
generation of reactive oxygen and nitrogen species followed by acute and chronic
inflammatory response) on the course of liver damage, oxidative/nitrative stress, acute and
chronic inflammatory response, signaling and cell death. We have also studied the effects of
CBD on inflammatory response and signaling of isolated mouse Kupffer cells (key resident
inflammatory cells of the liver) and on primary human sinusoidal endothelial cell activation
and attachment of neutrophils to the activated endothelium. Because it has been
demonstrated that CBD displayed unexpectedly high potency as an inverse agonist at
cannabinoid 2 (CB2) receptors in vitro [30], but in vivo it behaved rather as CB2 receptor
agonist in an obesity model [31], coupled with the known protective effects of CB2 receptors
on endothelial, inflammatory and perhaps some parenchyma cells against hepatic [27,28]
and other forms of I/R injury [32–35], we also explored the plausible role of CB2 receptors
in the effects of CBD on hepatic I/R injury using CB2 receptor knockout mice or
pharmacological tools. Our findings underscore the potential of CBD for the prevention/
treatment of hepatic and perhaps other forms of ischemic-reperfusion injury and
inflammatory diseases.
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Materials and methods
Hepatic ischemia reperfusion
Protocols involving the use of animals were approved by the Institutional Animal Care and
Use Committees and were performed in line with the National Institutes of Health (NIH)
guidelines for the care and use of laboratory animals. Male C57BL/6J mice (25–30g) were
anesthetized with pentobarbital (65 mg/kg i.p.). A midline laparotomy incision was
performed to expose the liver. The hepatic artery and the portal vein were clamped using
microaneurysm clamps. This model results in a segmental (70%) hepatic ischemia as
described [26–29]. Briefly, the liver was exposed by midline laparotomy and the hepatic
artery and the portal vein were clamped using an atraumatic micro-serrefine. This method of
partial ischemia prevents mesenteric venous congestion by allowing portal decompression
throughout the right and caudate lobes of the liver. The duration of hepatic ischemia was 60
min, after which the vascular clips were removed and liver was reperfused for 2h, 6h or 24
h, as indicated. Sham surgeries were identical except that hepatic blood vessels were not
clamped with a micro serrefine. The liver was kept moist at 37°C with gauze soaked in 0.9%
saline. Body temperature was maintained at 37°C using a thermoregulatory heating blanket
and by monitoring body temperature with a rectal temperature probe. Treatment with 3 and
10 mg/kg cannabidiol (CBD) or vehicle intraperitoneally (i.p.), started 2h before IR or given
as indicated in the text. Similar procedures were carried out in CB2−/− mice on C57BL/6J
background [27,36]. After reperfusion, blood was collected and liver samples were removed
and snap-frozen in liquid nitrogen for determining biochemical parameters or fixed in 4%
buffered formalin for histopathological evaluation [27].
Drugs
CBD was isolated as described [37]. All drugs were dissolved in vehicle solution (one drop
of Tween-80 in 3 ml 2.5% DMSO in saline) and injected i.p. 60 min prior the occlusion of
the hepatic artery and the portal vein. In a separate set of experiments, CBD (3 and/or 10
mg/kg) or vehicle was injected into the femoral vein right before the reocclusion or 90 mins
after. Vehicle solution was used in control experiments. For cell culture experiments, all
lipid-soluble drugs were dissolved in DMSO. All chemicals were from Sigma Chemical Co.
(St. Louis, MO, USA), except where it was mentioned.
Serum AST and ALT levels
The activities of aspartate amino-transferase (AST) and alanine amino-transferase (ALT),
indicators of liver damage, were measured in serum samples using a clinical chemistry
analyzer system (VetTest 8008, IDEXX laboratories, Westbrook, ME) [27–29].
Histological examination of liver sections
Liver samples were fixed in 4% buffered formalin. After embedding and cutting 4 μm slices,
all sections were stained with hematoxylin/eosin (HE). For myeloperoxidase (MPO) and
nitrotyrosine staning slides were deparaffinized, and hydrated in descending gradations of
ethanol, followed by antigen retrieval procedure. Next, sections were incubated in 0.3%
H2O2 in PBS to block endogenous peroxidase activity. The sections were then incubated
with anti-MPO (Biocare Medical, Concord, CA) or anti-nitrotyrosine (1:200 dilution;
Cayman Chemical, Ann Arbor, MI, USA) antibodies overnight at 4°C in a moist chamber.
Biotinylated secondary antibodies and ABC reagent were added as per the kit’s instructions
(Vector Laboratories, Burlingame, CA, USA). Color development was induced by
incubation with a DAB kit (Vector Laboratories) for 3–5 min, and the sections were counter-
stained with nuclear fast red as described [27,28,36]. Finally, the sections were dehydrated
in ethanol and cleared in xylene and mounted. The specific staining was visualized and
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images were acquired using microscope IX-81 with 20X, 40X and 100x objectives
(Olympus, Center Valley, PA). Histological evaluation was performed in a blinded manner.
Hepatic TUNEL immuno-histochemistry
Paraffin sections were dewaxed and in situ detection of apoptosis in the hepatic tissues was
performed by terminal deoxynucleotodyltransferase mediated nick-end labeling (TUNEL)
assay as per the instruction provided with the kit (Roche Diagnostics, Indianapolis, IN).
Nucleus was labeled with Hoechst 33242 and the TUNEL positive cells were observed using
confocal microscopy. Digital images were taken by a LSM Pascal confocal microscope
(Carl Zeiss, Thornwood, NY) at a resolution of 2,048 × 2,048 pixels. Images were captured
using 40X objectives and the optical section was <1 μm. The morphometric examination
was performed by two independent, blinded investigators. The number of apoptotic cells in
each section was calculated by counting the number of TUNEL-positive apoptotic cells in
10–12 of 40X fields/per condition from at least 3–5 independent samples/group [36].
Hepatic DNA fragmentation ELISA
The quantitative determinations of cytoplasmic histone-associated-DNA-fragmentation
(mono and oligonucleosomes) due to in vivo cell death were measured using ELISA kit
(Roche Diagnostics GmbH, Indianapolis, IN) [38,39].
Determination of hepatic poly(ADP-ribose) polymerase (PARP) activity
Hepatic PARP activity was assayed using a colorimetric kit according to manufacturer’s
protocol (Trevigen, Gaithersburg, MD) as described [40].
Real-Time PCR Analyses of mRNA
Total RNA was isolated from liver homogenate using TRIzol reagents (Invitrogen, Carlsbad,
CA) according to manufacturer’s instructions. The isolated RNA was treated with RNase-
free DNase (Ambion, Austin, TX) to remove traces of genomic DNA contamination. One
microgram of total RNA was reverse-transcribed to cDNA using the SuperScript II
(Invitrogen, Carlsbad, CA). The target gene expression was quantified with Power SYBER
Green PCR Master Mix using an ABI HT7900 real-time PCR instrument (Applied
Biosystems, Foster City, CA). Each amplified sample in all wells was analyzed for
homogeneity using dissociation curve analysis. After denaturation at 95°C for 2 min, 40
cycles were performed at 95°C for 10 s and at 60°C for 30 s. Relative quantification was
calculated using the comparative CT method (2-ΔΔCt method: ΔΔCt =ΔCt sample -ΔCt
reference). Lower ΔCT values and lower ΔΔCT reflect a relatively higher amount of gene
transcript. Statistical analyses were carried out for at least six to 15 replicate experimental
samples in each set.
Primers used were as follows:
TNF-α 5′-AAGCCTGTAGCCCACGTCGTA-3′ and 5′-
AGGTACAACCCATCGGCTGG-3′;
MIP1-α 5′-TGCCCTTGCTGTTCTTCTCTG-3′ and 5′-
CAACGATGAATTGGCGTGG-3′;
MIP2 5′-AGTGAACTGCGCTGTCAATGC-3′ and 5′-
AGGCAAACTTTTTGACCGCC-3′;
ICAM1 5′-AACTTTTCAGCTCCGGTCCTG-3′ and 5′-
TCAGTGTGAATTGGACCTGCG-3′;
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NOX2 5′-GACCATTGCAAGTGAACACCC-3′ and
5′AAATGAAGTGGACTCCACGCG3′;
iNOS 5′-ATTCACAGCTCATCCGGTACG-3′ and 5′-
GGATCTTGACCATCAGCTTGC-3′;
COX2 5′-GTGTATCCCCCCACAGTCAAA-3′ and 5′-
ACACTCTGTTGTGCTCCCGAA-3′;
and actin, 5′-TGCACCACCAACTGCTTAG-3′ and 5′-
GGATGCAGGGATGATGTTC-3′
Hepatic 4-hydroxynonenal (4-HNE) content
Lipid peroxides are unstable indicators of oxidative stress in cells that decompose to form
more complex and reactive compounds such as 4-hydroxynonenal (HNE), which has been
shown to be capable of binding to proteins and forming stable HNE adducts. There is also
emerging recent evidence implicating HNE in various key signaling processes [41,42]. HNE
in the hepatic tissues was determined using a kit (Cell Biolabs, San Diego, CA). In brief,
BSA or hepatic tissue extracts (10 μg/mL) are adsorbed onto a 96-well plate for 12 hrs at
4°C. HNE adducts present in the sample or standard are probed with anti-HNE antibody,
followed by an HRP conjugated secondary antibody. The HNE-protein adducts content in an
unknown sample is determined by comparing with a standard curve [43,44].
Isolation and stimulation of hepatic Kupffer cells
Livers were perfused in the deeply anaesthetized mouse and the livers were excised for
isolation of Kupffer cells [27]. Hepatic cellular contents were released from the stroma by
digestion with the perfusion medium (hepatocyte wash media) containing Collagenase type
1 (Sigma, St. Louis, MO) and 2 % Penicillin and Streptomycin (Invitrogen, Carlsbad, CA).
Kupffer cells were isolated using Optiprep gradient. Kupffer cell fraction was aspirated and
washed 2 times with RPMI 1640 medium. Homogenous Kupffer cells population was
obtained by using negative selection (anti-CD146) LS column according to manufacturer’s
instruction (Miltenyi Biotec, Auburn, CA). After additional washes, Kupffer cells were
plated on to 96 well or 6 well plates in RPMI 1640 media containing 10% FBS and
Penicillin-Streptomycin for overnight in CO2 incubator at 37°C and 5% CO2. Cells were
maintained for 2 hours with RPMI 1640 medium containing FBS (2%). CBD at indicated
concentrations were added 1 h prior to LPS treatment. Cells were treated for 6 hours with
LPS (Escherichia Coli O127:BB catalogue # L3129, Sigma Chemicals, St Louis, MO).
After the end of treatments, culture supernatants were removed and snap frozen in liquid
nitrogen and assayed for the TNF-α concentrations with the use of ELISA kit (Mouse TNF-
α; catalogue # SMTA00; R&D systems, Minneapolis, MN).
Immunoblot analyses
Liver tissues were homogenized in mammalian tissue protein extraction reagent (TPER,
Pierce, Rockford, IL) supplemented with protease and phosphatase inhibitors (Roche
Diagnostics, Indianapolis, IN). Kupffer cells were lyzed in RIPA buffer supplemented with
protease and phosphatase inhibitors. Blots were probed with either rabbit p38 MAPK,
phospho p38 (Thr 180/Tyr 182) MAPK, IκB-α, phospho (Ser 32/36) IκB-α, SAPK/JNK,
phospho SAPK/JNK (Thr183/Tyr185), (Cell Signaling Technology, Beverly, MA) and were
used at 1:1000 dilution and incubated overnight at 4°C. After subsequent washing with
PBST, the membranes were probed with appropriate secondary antibodies conjugated with
HRP (Pierce, Rockford, IL) and incubated 1 h at RT. Then the membranes were developed
using Super Signal-West Pico Substrate chemiluminescence detection kit (Pierce, Rockford,
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IL). To confirm uniform loading, membranes were stripped and re-probed with β-actin
(Chemicon, Ramona, CA).
Measurement of NF-κB activation by gel shift assay
The NF-κB activation in the liver tissue samples was performed using the reagents and the
accompanying protocols from Panomics, Inc. (Fremont, CA). In brief, the nuclear extracts
isolated by NE-PER kit (Pierce, Rockford, IL) from liver were incubated with biotin-labeled
transcription factor probe, and then the protein/DNA complexes were separated on a non-
denaturing polyacrylamide gel. The gel was transferred to a Biodyne A nylon membrane
(Pierce, Rockford, IL) and detected using streptavidin-HRP and chemiluminescent substrate.
The shifted bands corresponding to the protein/DNA complexes were identified relative to
the unbound dsDNA. The illuminated images were visualized in VersaDoc MP4000
imaging system (BioRad, Hercules, CA).
Determination of mitochondrial complex I activity
Microplate assay kit (MitoSciences Inc., Eugene, OR) were used to determine the activity of
oxidative phosphorylation Complex I according to the manufacturer’s instructions. The
Complex-I enzyme was immunocaptured within the wells of the microplate and activity was
determined colorimetrically by following the oxidation of NADH to NAD+ and the
simultaneous reduction of a dye which leads to the absorbance change at 450 nm. Complex
activity was expressed as percent activity compared to the liver samples of the vehicle
treated mice.
Cell Surface ICAM-1 and VCAM-1 Expression Assay
Cell surface expression of ICAM-1 and VCAM-1 in the human liver sinusoidal endothelial
cells (HLSEC) was measured by in situ ELISA as described [27,28,45]}. In brief, HLSEC
cells were grown in 96-well plates. After treatments as described in figure, in situ ELISA
was performed with anti-mouse ICAM-1 or VCAM-1 monoclonal antibodies (1:1,500
dilution; R&D Systems) and by measuring the absorbance colorimetrically at 450 nm using
the horseradish peroxidase-3,3′,5,5′-tetramethylbenzidine developing system (Sigma, St.
Louis, MO). Each treatment was performed in triplicate, and the experiments were repeated
three times.
(PMN)–endothelial cell adhesion
Neutrophil adhesion to endothelial cells was performed as described [27] with modifications
in the protocol. In brief, HLSECs were grown to confluence in 24-well plates and treated
with TNFα and cannabidiol as described in the text. Then, PMN were labeled with 2.5 μM
Calcein-AM (Molecular Probes–Invitrogen, Carlsbad, CA) for 1 h at 37°C in RPMI 1640
containing 1% FBS. HLSECs were washed twice with HLSECs basal medium and covered
with 400 μl of HLSECs basal medium. Then 5×104/100 μl labeled PMN cells were added to
HLSECs and incubated for 1 h at 37°C. After incubation, the monolayer was carefully
washed with PBS to remove the unbound PMN. The adherent PMNs were documented by
Olympus IX 81 fluorescent microscope using 20X objective (Olympus America, Center
Vally, PA). Three fields were captured in all experimental conditions. Individual treatments
were performed in duplicate, and the entire set of experiments was repeated twice. The
number of adherent PMN cells were counted using NIH Image J software and the values
were expressed as PMN adhered/field.
Hepatic protein nitrotyrosine (NT) content determination
Nitrotyrosine formation was initially considered as a specific marker of in vivo peroxynitrite
generation, but now it is rather used as a collective index of nitrative stress, because other
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pathways have also been proposed to be involved in its formation (e.g., myeloperoxidase in
certain inflammatory conditions) [46–48]. Hepatic nitrotyrosine content was determined by
nitrotyrosine ELISA according to the protocol supplied with the kit (Hycult Biotechnology,
Cell Sciences, Canton, MA) as described [40,44].
Statistical analysis
Results are expressed as mean±SEM. Statistical significance among groups was determined
by one-way ANOVA followed by Newman-Keuls post hoc analysis using GraphPad Prism
5 software (San Diego, CA). Probability values of P<0.05 were considered significant.
Results
Cannabidiol attenuates markers of hepatic I/R injury (ALT, AST)
For assessments of hepatocellular damage of the post-ischemic liver, the serum
transaminases (AST and ALT) activities were measured. After 1 hour of ischemia and a
subsequent 2 or 6 hours of reperfusion (I/R 2 h or I/R 6h), a dramatic increase in liver
enzyme activities were observed in vehicle-treated C57Bl6J mice as compared with sham-
operated controls (Figure 1A, B). Pretreatment with CBD (3–10 mg/kg, CBD 3 and 10
respectively) 2 hours before the induction of the ischemia dose-dependently attenuated the
serum transaminase elevations at 2 and 6 hours of reperfusion compared to vehicle (ALT
level decreased by ~11% with CBD 3 mg/kg and by ~68% with CBD 10 mg/kg whereas
AST decreased by 3% and 48% respectively at 2h reperfusion. ALT level decreased by 84%
with CBD 3 mg/kg and by 70% with CBD 10 mg/kg, whereas AST decreased by 73% and
68%, respectively at 6 hours of reperfusion (Figure 1). Furthermore, pre-treatment with
CBD 3 mg/kg of CB2−/− knockout mice, which had significantly (~53–67%) increased
damage at 6 hours of reperfusion (this is the time of the peak serum ALT/AST elevations/
injury following induction of the ischemia), resulted in similar degree of protection seen in
their wild type littermates (reduction of serum ALT/AST by ~81% and 77%, respectively),
excluding any significant role of CB2 receptors in the beneficial effects of CBD. CBD alone
had no effects on ALT and AST levels compared to the vehicle-treated group. CBD
treatment given right after the induction of the ischemia (Figure 2A) or at 90 minutes of
reperfusion (Figure 2B) was still able to attenuate, though to a lesser extent, the hepatic
injury measured at 6 hours of reperfusion.
Cannabidiol improves I/R-induced histological damage
I/R induced marked coagulation necrosis after 24 hours of reperfusion (lighter areas, with
marked inflammatory cell infiltration), which was dramatically reduced and became more
focal in CBD treated mice. CBD treatment or vehicle alone had no effect on the
histopathology of the liver (Figure 3).
Cannabidiol attenuates I/R-induced hepatic cell death
TUNEL staining of liver sections at 24 hours of reperfusion showed significant increase in
apoptotic bodies, which was attenuated by CBD (10 mg/kg) pretreatment of mice (Figure
4A). The quantification of cell death demonstrated ~10 fold increase in apoptotic cells after
24 hours of reperfusion, which was attenuated by ~70% with CBD pretreatment. DNA
fragmentation (Figure 4B) and PARP activity (Figure 4C) showed time-dependent increases
in liver homogenates following 2, 6 and 24 hours of reperfusion (DNA fragmentation
increased by ~2.4, ~4.7 and ~10.9 folds at 2, 6 and 24 hours of reperfusion, respectively,
while PARP activity by ~3.7, ~3.8 and ~2.8 folds), which were markedly attenuated by CBD
(10 mg/kg) pretreatment (DNA fragmentation decreased by 33%, 49% and 56%, while
PARP activity by ~44%, 45% and 34%, respectively).
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Cannabidiol attenuates I/R-induced hepatic pro-inflammatory chemokine, cytokines and
adhesion molecule expression
I/R greatly increased the expression of mRNA of chemokines MIP-1α (CCL3) and MIP-2
(CXCL2) in liver tissue as documented by Real-time PCR, which was attenuated by 10 mg/
kg CBD (Figure 5). Hepatic MIP-1α mRNA increased to the highest level at 2 hours of
reperfusion (by ~25.7 folds) and gradually decreased by 24 hours of reperfusion to the less
than half. CBD treatment decreased hepatic peak MIP-1α mRNA level at 2 hours of
reperfusion by 66% (Figure 5A). MIP2 increased to the peak level at 2 hours of reperfusion
(~31.8 fold increase) and gradually decreased by 24 hours of reperfusion. CBD treatment
attenuated the increase of MIP2 mRNA level (~7.3 fold compared to control) at 2 hours of
reperfusion, as well as markedly attenuated I/R values at 6 and 24 hours of reperfusion
(Figure 5B).
Real-time PCR analyses of adhesion molecule ICAM-1 and cytokine TNF-1α mRNA
demonstrated markedly increased expression in liver tissue after I/R, peaking at 2 hours of
reperfusion (~14 and 40 folds increases, respectively) and gradually declining thereafter
(Figure 6 A, B). CBD pretreatment decreased the I/R-induced increased ICAM-1 and
TNF-1α mRNA expression to ~50%, and 25% of their initial values at 2 hours of
reperfusion, respectively. CBD also markedly attenuated these values at 6 and 24 hours
following reperfusion (Figure 6 A, B).
Cannabidiol attenuates I/R-induced marked neutrophil infiltration
Neutrophils are important mediator of the delayed tissue injury following I/R. An indicator
of neutrophil infiltration is the myeloperoxidase activity (MPO). In sham-operated wild-type
mice, or in mice following 2 and 6 hours of reperfusion (not shown) the liver MPO staining
was barely detectable, because infiltrating inflammatory cells were not yet present (Figure
7). In contrast, following 24 hours of reperfusion there was marked increase in infiltrating
MPO positive immune cells, which was largely attenuated by CBD.
Cannabidiol treatment attenuates I/R-induced hepatic nuclear factor-κB activation
As shown in Figure 8A, gel shift assay confirmed the hepatic NF-κB activation in I/R. The
CBD treatment attenuated the p65NF-κB nuclear translocation (Figure 8A).
Cannabidiol attenuates I/R-induced p38 MAPK and JNK activation
There was marked increase in the p38MAPK and c-Jun N-terminal kinase (JNK) activation
in I/R liver tissue of mice at 2h and 6h following I/R injury, and CBD pretreatment at 10
mg/kg attenuates these increases (Figure 8B).
Cannabidiol decreases I/R-induced increased oxidative stress and attenuates I/R-induced
decreased mitochondrial complex I activity
The rate of lipid peroxidation was negligible in sham-operated mouse livers, as indicated by
the low levels of HNE adducts. Hepatic HNE adducts increased time dependently to ~3, 4
and 6.4 folds at 2, 6 and 24 hours of reperfusion, which were significantly attenuated by
CBD (10 mg/kg) pretreatment to ~2, 1.9 and 2.9 folds increases (compared to sham),
respectively (Figure 9A). Mitochondrial complex I activity was decreased by 63%, 45% and
39% at 2, 6 and 24 hours of reperfusion, respectively, indicating dysfunction (Figure 9B).
Pretreatment with CBD at 10 mg/kg restored the I/R-induced decrease in mitochondrial
complex I activity at all time points of the reperfusion studied to normal level. The
expression of the isoform of the superoxide generating NADPH oxidase enzyme, the
gp91phox (NOX2), was also gradually increased to the peak level at 24 hours of reperfusion
(~5.1 fold increase). CBD treatment markedly decreased I/R-induced peak in gp91phox
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level to ~2.2 fold at 24 hours of reperfusion (~56% decrease), as well as attenuated I/R
values at 6 hours of reperfusion (Figure 9C).
Cannabidiol attenuates I/R-induced hepatic iNOS, cyclooxygenase 2 (COX2) expressions
and nitrotyrosine content
Cyclooxygenase 2 (COX2) expression gradually increased at 2 (~3.1 fold increase), 6 (~5.4
fold increase) and 24 hours of reperfusion (~9.8 fold increase). CBD treatment decreased I/
R-induced hepatic COX2 mRNA increases by 22%, 57% and 53% at 2, 6 and 24 hours of
reperfusion, respectively (Figure 10A).
I/R increased the expression of mRNA of iNOS (NOS2) in liver tissues as documented by
Real-time PCR, which was attenuated by 10 mg/kg CBD (Figure 10B). Hepatic iNOS
mRNA gradually increased to the highest level at 24 hours of reperfusion (~5.4 folds
increase). CBD treatment attenuated hepatic I/R-induced iNOS mRNA levels at 6 and 24
hours of reperfusion by more than 50% (Figure 10B).
Nitrotyrosine modification of protein, a marker for peroxynitrite formation and/or nitrative
stress, increased to ~2.2, 4.5 and 7.1 folds at 2, 6 and 24 hours of reperfusion, and was
attenuated by CBD pretreatment at 10 mg/kg by 20, 33 and 50%, respectively (Figure 10C).
I/R also induced time-dependent marked increases in liver nitrotyrosine staining (Figure 11),
while livers of sham operated animals were negative. Strong nitrotyrosine staining was
present in endothelial cells, hepatocytes around the vessels in the damaged areas, as well as
in the inflammatory infiltrate (neutrophil granulocytes, macrophages and Kupffer cells).
CBD markedly attenuate the I/R-induced nitrotyrosine formation.
CBD attenuates the endotoxin induced NFκB activation and TNF-α production in isolated
mouse Kupffer cells
Kupffer cells were isolated from mice as described in the Methods section, and then treated
with bacterial lipopolysaccharide (LPS, 100 ng/ml) in the presence or absence of CBD. As
shown in Figure 12, LPS treatment augmented NFκB activation characterized by increased
degradation and phosphorylation of IκBα, which was suppressed by treated with CBD. LPS
treatment drastically enhanced TNF-α production in the Kupffer cells, which was attenuated
in a dose-dependent manner by CBD.
CBD attenuates the TNF-α-induced adhesion molecules expression and
polymorphonuclear cells (PMN) adhesion to human sinusoidal endothelial cells (HLSEC)
Treatment of HLSEC cells with TNF-α for 6 hours markedly enhanced the production of
adhesion molecules such as ICAM-1 and VCAM-1 (Figure 13) and PMN adhesion (Figure
14). This was mitigated when cells were treated with CBD. To rule out the potential role of
cannabinoid receptors in mediating CBD’s effects, specific cannabinoid receptor inverse
agonists/antagonists such as SR141716 (SR1 for CB1 receptor) and SR144528 (SR2 for CB2
receptor) were used. Interestingly, when HLSECs were treated with TNF-α, in the presence
of SR1, there was slight reduction in the adhesion molecule expression and PMN adhesion,
while SR2 had only a small effect on VCAM-1 but not ICAM-1 or PMN adhesion. More
importantly, CBD alone had greater anti-inflammatory effect in endothelial cells than SR1
or SR2, and this protection was not reversed by either SR1 or SR2 (it was rather additive
with SR1), suggesting that CB1/2 receptors were not involved in mediating these effects. The
beneficial effect of SR1 could be attributed to its known anti-inflammatory action [21].
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Discussion
Hepatic I/R injury is a major clinical problem implicated in the liver failure associated with
liver transplantation, hepatic surgery and circulatory shock, with unfortunately only limited
therapeutic options. Cannabidiol, is a nonpsychotropic component of marijuana, which has
been shown to exert antioxidant and anti-inflammatory effects both in vitro and in various
preclinical models of neurodegeneration and inflammatory disorders, independent from
conventional CB1 and CB2 receptors (reviewed in [13,15]). In the present study, we
demonstrate that CBD exerts protective effect against liver I/R reperfusion damage by
attenuating major pro-inflammatory and stress signaling pathways, as well as oxidative/
nitrative stress and cell death.
Initially, the destructive effects of I/R is inflicted by the generation of superoxide and other
forms of reactive oxygen species (ROS) following reoxygenation during reperfusion from
the activation of various sources (e.g. xathine oxidoreductases [49,50]). This also leads to
early impairment of the activities of the enzymes of the mitochondrial respiratory chain,
mitochondrial dysfunction, allowing more ROS to leak out of the respiratory chain [29,50].
Consistently with previous studies demonstrating mitochondrial dysfunction in various
forms of I/R [29,51,52], we found marked depression of mitochondrial complex I activity in
the livers exposed to ischemia followed by reperfusion. This decreased complex I activity
was most pronounced 2 hours following ischemia, but also persisted at 6 and 24 hours of
reperfusion. In agreement with previous studies establishing that NADPH oxidase-derived
superoxide (particularly gp91phox/NOX2-derived (gp91phox is abundantly present in
various inflammatory cells including neutrophil granulocytes)), plays an important role in
the development of hepatic I/R-induced injury [4,11,12,26], we also found significantly
increased expression of mRNA of gp91phox at 6 and 24 hours of reperfusion. The peak
increase in gp91phox mRNA expression occurred 24 hours following the ischemic insult
coinciding with the marked inflammatory cell infiltration in damaged livers. However, the
absence of significantly increased gp91phox mRNA expression 2 hours following ischemia,
coupled with markedly depressed mitochondrial complex I activity, support the view that at
early stage of reperfusion injury mitochondria play important role in reactive oxygen species
(ROS) generation.
The increased superoxide and NO generation during early hepatic reperfusion (the latter
being most likely derived from increased iNOS induction) favors the formation of the potent
oxidant peroxynitrite [53] via a diffusion limited reaction of superoxide with nitric oxide
(NO) [54], further impairing mitochondrial [55] and cellular functions and increasing ROS
generation [7,29,50]. Consistently with several recent studies demonstrating markedly
enhanced iNOS gene/protein expressions during hepatic I/R [56–60], we found significant
time-dependent increases in the liver iNOS mRNA expression at 2, 6 and 24 hours of
reperfusion, peaking at 24 hours when the massive inflammatory cell infiltration occurred.
There was also significant increase in hepatic nitrotyrosine (NT) content as early as at 2
hours of reperfusion, with further increase at 6 hours and dramatic enhancement at 24 hours
of reperfusion. While nitrotyrosine has been considered a marker of peroxynitrite formation
previously, there is some evidence that heme-protein peroxidase activity, in particular
neutrophil-derived myeloperoxidase (MPO), may significantly contribute to nitrotyrosine
formation in vivo via the oxidation of nitrite to nitrogen dioxide under certain inflammatory
conditions [46,47], therefore it is rather used as a collective index of nitrative sress [3].
Since the neutrophil recruitment is known to occur in this hepatic I/R model predominantly
from 6 hours of reperfusion (peaking between 12–24 hours), it is not very likely that the
latter mechanism was significantly involved in the increased hepatic nitrotyrosine content/
staining observed at 2 and 6 hours of reperfusion compared to sham operated animals,
however it may contribute to the additional elevation observed at 24 hours, at a time when
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there is a profound increase in the MPO positive infiltrating neutrophils. This is also
supported by our results clearly demonstrating absence of infiltrating inflammatory cells
(including MPO positive cells) at 2 and 6 hours of reperfusion in liver tissues. Furthermore,
at earlier time points of reperfusion (2 and 6 hours) the NT staining is clearly localized in
endothelial cells and perivascular hepatocytes which are the primary targets of I/R-induced
injury (the staining being stronger at 6 hours of reperfusion when gp91phox and iNOS
mRNA expressions are also elevated). At 24 hours of reperfusion we observed further
dramatic enhancement of hepatic NT content/staining in endothelial cells and perivascular
hepatocytes in the damaged areas, as well as in infiltrating (largely MPO positive)
inflammatory cells in the necrotic areas. Importantly, the time-dependent increases in
hepatic NT content/staining paralleled with increased expressions of superoxide generating
gp91phox and iNOS, as well as with increased hepatic HNE adduct levels (marker of lipid
peroxidation/oxidative stress [41,42]). Thus, it is very likely that the above described
increased NT content/staining during reperfusion originates, at least in part, from increased
peroxynitrite generation. Importantly, NO which is readily diffusible at a distance of several
cells, irrespective of its source can rapidly react with superoxide (even produced in
neighboring cells) to form peroxynitrite, resulting in decreased NO bioavailability with
consequent loss of its protective effects [3]. It should also be noted that under various pro-
inflammatory conditions both eNOS and iNOS may also be uncoupled and generate
additional ROS aggravating the tissue damage [3]. Increasing evidence suggests that
peroxynitrite during I/R injury may modulates/trigger various key stress signaling (e.g. p38
MAPK, JNK), pro-inflammatory (e.g. nuclear factor kappa B (NF-KB)) and cell death
signaling pathways [3,61–64], promoting cell death (both apoptotic and necrotic).
Indeed, sustained ROS/RNS generation during hepatic reperfusion activates important stress
signaling (e.g. p38MAPK, JNK) [65] and pro-inflammatory pathways (e.g. NF-KB
[4,26,57,65–67], COX-2 [68,69]) in various cell types, in turn rmodulating/regulating
important inflammatory and cell death processes. In agreement with these observations, we
demonstrate time-dependent activation of these pathways at 2, 6 and/or 24 hours of
reperfusion in the liver. After a more prolonged period of reperfusion, increased amounts of
pro-inflammatory chemokines and cytokines are produced from activated Kupffer cells
(resident macrophages of the liver) and endothelium leading to the priming and recruitment
of neutrophils and other inflammatory cells, into the liver vasculature upon reperfusion,
attachment to the activated endothelium and consequent activation resulting in further ROS/
RNS generation and release of pro-inflammatory mediators leading to endothelial damage
and dysfunction [4,8]. Subsequently, adherent inflammatory cells transmigrate through the
injured endothelium, attach to hepatocytes, and become fully activated to release oxidants
and proteolytic enzymes, which in turn triggers the intracellular oxidative/nitrative stress
and mitochondrial dysfunction in hepatocytes, eventually culminating in cell death (both
apoptotic and necrotic), as also demonstrated in our report. Hepatic I/R also leads to
significant reduction of endothelial NO synthase activity in sinusoidal endothelial cells
during I/R [70–73] resulting in an imbalance between sinusoidal vasoconstrictors (e.g.,
endothelins) and vasodilators (NO) in the liver, creating a situation favoring sinusoidal
vasoconstriction and injury during reperfusion [4,70–72,74]. In agreement with our recent
results, and as already mentioned above, hepatic I/R also activates Kupffer cells, which in
concert with activated inflammatory cells then produce proinflammatory cytokines, free
radicals, oxidants, and large amounts of NO due to iNOS expression [4,56–60,75], leading
to more sustained formation of peroxynitrite and decreased NO bioavailability. These events
lead to further activation of endothelial cells, neutrophils, and hepatocytes, resulting in
amplified ROS/RNS generation in the delayed phase of hepatic I/R aggravating the cell
death of hepatocytes and consequent organ injury.
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Consistent with the above mentioned sequel of pathological events and previous reports
using the same or very similar models [26–29], we have found increased serum alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) activities (markers of liver
injury), hepatic oxidative/nitrative stress (HNE, NT content/staining, gp91phox and iNOS
mRNA), mitochondrial dysfunction (decreased complex I activity), enhanced acute
inflammatory response (TNF-α, COX-2, MIP-1α/CCL3, MIP-2/CXCL2, ICAM-1/CD54,
mRNA levels, NF-KB), and stress signaling (p38 MAPK and JNK) activation at 2 and/or 6
hours of reperfusion. This was followed by tissue neutrophil infiltration and cell death
(DNA fragmentation, PARP activity, and TUNEL) at 24 hours of reperfusion. Indeed, both
oxidative and nitrative stress appeared to peak at 24 hours of reperfusion, as well as
apoptotic cell death (DNA fragmentation and deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL)), while the poly(ADP-ribose) polymerase (PARP) activity was already at
peak at 2–6 hours, indicating that the predominant type of cell death at the earlier time
points of reperfusion is necrotic. The latter is also supported by peak observable levels of
serum ALT and AST (marker of hepatocyte necrosis) at 6 hours of reperfusion in our model,
and gradual return close to normal levels thereafter by 24 hours.
We found that CBD, given prior to the induction of I/R, significantly attenuated the
elevations of serum liver transaminases (ALT/AST), decreased tissue oxidative and nitrative
stress (HNE, NT content/staining, gp91phox and iNOS expressions), attenuated acute and
chronic hepatic inflammatory response (TNF-α, MIP-1α/CCL3, MIP-2/CXCL2, ICAM-1/
CD54, COX-2 mRNA levels, NF-KB activation, and tissue neutrophil infiltration), stress
signaling (p38 MAPK, JNK), and cell death (DNA fragmentation, PARP activity and
TUNEL). CBD also exerted similar protective effects in CB2 knockout mice against I/R
injury, indicating that its protective effects were not mediated by CB2 receptors. It is also
unlikely that the in vitro described inverse agonistic property of CBD at CB2 receptors
contributed to its beneficial effect observed in the current in vivo study, because CB2 inverse
agonists by themselves are not attenuating the I/R-induced tissue (including hepatic) injury,
but are able to prevent the protective effect of pure CB2 agonist in the same models [35].
Importantly from a clinical point of view, the protective effects of CBD against liver damage
were also preserved when it was given right after the ischemic episode up to 90 minutes of
reperfusion.
The beneficial effects of CBD against I/R injury can only be explained in part by its direct
antioxidant properties [24,76]. In fact, in the first study demonstrating its direct and indirect
antioxidant effects [24], CBD was more protective against glutamate-induced neurotoxicity
than any of the well-know antioxidants (e.g., ascorbate or α-tocopherol), indicating
additional cytoprotective effects of CBD beyond its antioxidant properties. Moreover, pro-
oxidant effects of CBD were also recently described in various immune cells (e.g.
lymphocytes) in vitro [77,78], which may contribute to apoptosis induction in these cells, an
overall anti-inflammatory response. CBD has also been reported to exert potent anti-
inflammatory effects in numerous inflammatory disease models in which conventional
antioxidants are not very effective (e.g., in autoimmune arthritis [13,15,79]), and was
recently shown to attenuate key pro-inflammatory signaling processes (e.g. NF-KB
activation) and/or its consequences (e.g. adhesion molecules, COX-2, iNOS expressions,
etc.) in kidneys with nephropathy [38], diabetic hearts [25], human cardiomyocytes exposed
to high glucose [25], and in bacterial lipopolysaccharide/endotoxin (LPS)-activated
microglia cells [80], likewise in livers exposed to I/R injury in the current report. Notably,
the most prominent effects of CBD in our in vivo liver I/R injury model were the
suppression of the acute inflammatory response (orchestrated mostly by Kupffer cells and
activated endothelium), as well as the marked attenuation of the delayed inflammatory cell
infiltration. In further support of the anti-inflammatory effects of this natural constituent of
marijuana, we also provide in vitro evidence that CBD attenuates LPS-triggered NF-KB
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activation and TNF-α production in isolated Kupffer cells, as well as the adhesion molecules
(ICAM-1 and VCAM-1) expression in primary human liver sinusoidal endothelial cells
stimulated with TNF-α, likewise the attachment of human neutrophils to the activated
endothelium. These protective effects of CBD were preserved in CB2 knockout mice and
were not prevented by CB1/2 antagonists in vitro.
Although following intraperitoneal injection numerous biotransformation products of CBD
has been reported in mouse livers, and over 50 metabolites were identified in the urine with
considerable variations among rat, dog and man, their biological activities and significance
are largely elusive [81,82]. On the basis of numerous in vitro studies (both in cell free and
cellular systems; even though the metabolism of CBD can not be excluded in some cells in
vitro), it is very likely CBD exerts direct anti-inflammatory and antioxidant effects.
However, the indirect protective effect of its certain metabolites in in vivo models can not be
excluded, which deserves further exploratory studies.
Collectively, our results indicate that CBD may represent a novel protective strategy against
I/R-induced injury and inflammatory diseases by attenuating the acute and chronic pro-
inflammatory response, oxidative/nitrative stress, cell death and interrelated signaling.
Furthermore, our results also underline the importance of the careful evaluation of the
markers of oxidative/nitrative stress, inflammation, cell death and signaling processes at
various time points of reperfusion, since these may show considerable time-dependent
differences.
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Figure 1. Cannabidiol pretreatment decreases liver I/R injury
Panel A-B: Serum transaminase ALT (A) and AST (B) levels in sham operated mice treated
with vehicle (veh) or CBD (n=5/group) or in mice exposed to 1 h of hepatic ischemia
followed by 2 or 6 hours of reperfusion pretreated with vehicle or CBD (3 or 10 mg/kg,
n=7–12/group). *P<0.05 vs. vehicle-sham group; #P<0.05 vs. corresponding control or
cannabinoid 2 receptor knockout (CB2KO) mice exposed to vehicle-I/R.
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Figure 2. Cannabidiol treatment after ischemia or at 90 mins of reperfusion decreases liver I/R
injury
Panel A and B: Serum transaminase ALT and AST levels in mice exposed to 1 h of hepatic
ischemia followed by 6 hours of reperfusion treated with vehicle or CBD (3 or 10 mg/kg,
n=5–7/group) either right after the ischemia before reperfusion (panel A) or at 90 minutes of
reperfusion (panel B). #P<0.05 vs. corresponding mice exposed to vehicle-I/R.
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Figure 3. Cannabidiol decreases histological damage 24h following ischemia
Hematoxylin and eosin staining of representative liver sections of sham mice treated with
vehicle (sham) or CBD (CBD), and mice exposed to 1 hour of ischemia followed by 24
hours of reperfusion, treated with vehicle (I/R) or CBD (I/R+CBD). A similar histological
profile was seen in three to five livers/group. Upper row of images depicts 200x
magnification, while the lower one 400x magnification.
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Figure 4. Cannabidiol attenuates I/R-induced enhanced hepatic cell death
Panels A: Representative TUNEL staining 24 h following I/R injury. TUNEL positive nuclei
of cells are light blue/white (colocalization of TUNEL (green staining) with nuclear staining
(blue)), whereas the dark blue staining represents the staining of nuclei of normal cells.
Right panel: quantification of hepatic TUNEL staining. Results are mean±SEM of 10–12
frames/group from 3–4 different animals/group. *P<0.05 vs. sham vehicle; #P<0.05 vs. I/R
vehicle mice.
Panels B: Time-dependent increase of hepatic DNA fragmentation demonstrated following
I/R injury and attenuation by CBD pretreatment at 10 mg/kg. Results are mean±SEM of
n=8/group.
*P<0.05 vs. sham vehicle; #P<0.05 vs. corresponding I/R mice.
Panels C: Time dependent changes in hepatic PARP activity following I/R, and attenuation
of the observed increases by pretreatment with CBD at 10 mg/kg. Results are mean±SEM of
n=8/group. *P<0.05 vs. sham vehicle; #P<0.05 vs. corresponding I/R mice.
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Figure 5. Cannabidiol attenuates I/R-induced acute pro-inflammatory chemokines response in
the liver
Panels A: Real-time PCR shows significant increase of chemokine MIP-1α (CCL3) mRNA
level at 2 hours of reperfusion (IR 2h), and a decrease at 24 hours of reperfusion (IR 24h).
Pretreatment with CBD at 10 mg/kg significantly attenuates the I/R-induced increased pro-
inflammatory chemokine levels at all time points of the reperfusion studied (2, 6 and 24
hours).
Panels B: Real-time PCR shows significant increase of chemokine MIP-2 (CXCL2) mRNA
level at 2 h of reperfusion (IR 2h), and a decrease at 24 hours of reperfusion (IR 24h).
Pretreatment with CBD at 10 mg/kg attenuates the I/R-induced increased pro-inflammatory
chemokine levels at all time points of the reperfusion studied (2, 6 and 24 hours).
Results are mean±SEM of 6–12 mice/groups. *P<0.05 vs. vehicle-sham group; #P<0.05 vs.
corresponding vehicle-I/R mice.
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Figure 6. Cannabidiol attenuates I/R-induced increased adhesion molecule expression and acute
pro-inflammatory cytokine TNF-α response in the liver
Panels A: Real-time PCR shows significant increase of hepatic adhesion molecule ICAM-1
mRNA level at 2 hours of reperfusion (IR 2h), which was further attenuated at 6 and 24
hours of reperfusion (I/R 6h and 24h). Pretreatment with CBD at 10 mg/kg significantly
attenuates the I/R-induced increased hepatic ICAM-1 expression at all time points of the
reperfusion studied (2, 6 and 24 hours).
Panels B: Real-time PCR shows significant increase of hepatic pro-inflammatory cytokine
TNF-α mRNA level at 2 h of reperfusion (IR 2h), and a gradual decrease with time.
Pretreatment with CBD at 10 mg/kg attenuates the I/R-induced increased hepatic TNF-α
mRNA level at all time points of reperfusion studied (2, 6 and 24 hours).
Results are mean±SEM of 6–12 mice/groups. *P<0.05 vs. vehicle-sham group; #P<0.05 vs.
corresponding vehicle-I/R mice.
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Figure 7. Cannabidiol decreases I/R-induced neutrophil infiltration after I/R injury
Myeloperoxidase staining (brown) of representative liver sections of sham mice pretreated
with vehicle (sham) or CBD (CBD), and mice exposed to 1 hour of hepatic ischemia
followed by 24 hours of reperfusion with vehicle (I/R) or CBD (I/R+CBD) pretreatment. I/R
followed by 24 hours of reperfusion dramatically increased neutrophil infiltrationin in the
livers, which was attenuated by CBD pretreatment. In livers of sham operated mice with or
without pretreatment there was no tissue inflammatory cell infiltration, likewise only a very
few inflammatory cells were present in the lumen of some vessels at 2 hours and 6 of
reperfusion. Slides were counterstained by nuclear fast red. A similar histological profile
was seen in three to five livers/group. Upper row of images depicts 200x magnification,
while the lower one 400x magnification.
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Figure 8. Cannabidiol attenuates I/R-induced hepatic NF-κB activation and p38 MAPK and
JNK phosphorylation
Panel A: The gel shift assay demonstrates NF-κB activation at 2 and 6 hours of reperfusion
(I/R 2h and I/R 6h) which was attenuated at 24 hours reperfusion (I/R 24h). CBD
pretreatment at 10 mg/kg attenuates these activation at all time points of reperfusion studied.
Panel B: Marked increase in the p38MAPK and c-Jun N-terminal kinase (JNK) activation in
I/R liver tissues of mice at 2 and 6 hours following I/R injury, which are attenuated by CBD
pretreatment at 10 mg/kg. β-actin is used as loading control.
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Figure 9. Cannabidiol decreases the I/R-induced increased hepatic oxidative stress and restores
decreased mitochondrial complex I activity
Panel A: HNE adduct, a marker for lipid peroxidation/oxidative stress, increases with time
following I/R injury, and CBD pretreatment at 10 mg/kg attenuates these increases at all
time points of reperfusion studied (2, 6 and 24 hours). Results are mean±SEM of 8 mice/
groups. *P<0.05 vs. vehicle-sham group; #P<0.05 vs. corresponding vehicle-I/R mice.
Panel B: Mitochondrial complex I activity decreased at 2 hours of reperfusion which
partially recovered at 6 and 24 hours of reperfusion. Pretreatment with CBD at 10 mg/kg
attenuated the I/R-induced decreased mitochondrial complex I at all time points of the
reperfusion studied (2, 6 and 24 hours). Results are mean±SEM of 6–7 mice/groups.
*P<0.05 vs. vehicle-sham group; #P<0.05 vs. corresponding vehicle-I/R mice.
Panel C: Real-time PCR shows significant increase of hepatic gp91phox mRNA level from
6 hours of reperfusion (IR 6h), which peaks at 24 hours (IR 24h). Pretreatment with CBD at
10 mg/kg significantly attenuates the I/R-induced increased liver gp91phox mRNA
expression at 6 and 24 hours of reperfusion. Results are mean±SEM of 8–10 mice/groups.
*P<0.05 vs. vehicle-sham group; #P<0.05 vs. corresponding vehicle-I/R mice.
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Figure 10. Cannabidiol attenuates I/R-induced COX-2 and iNOS mRNA expression and
nitrative stress in the liver
Panel A: Real-time PCR shows significant time-dependent increases of hepatic COX-2
mRNA level at 2, 6 and 24 hours of reperfusion (IR 2h, 6h and 24h). Pretreatment with CBD
at 10 mg/kg attenuates the I/R-induced increase in COX-2 mRNA expression at all time
points of the reperfusion studied (2, 6 and 24 hours). Results are mean±SEM of 6–10 mice/
groups. *P<0.05 vs. vehicle-sham group; #P<0.05 vs. corresponding vehicle-I/R mice.
Panel B: Real-time PCR shows significant time-dependent increases of hepatic iNOS
mRNA level at 2, 6 and 24 hours of reperfusion (IR 2h, 6h and 24h). Pretreatment with CBD
at 10 mg/kg attenuates the I/R-induced increase in iNOS mRNA at all time points of the
reperfusion studied (2, 6 and 24 hours). Results are mean±SEM of 6–10 mice/groups.
*P<0.05 vs. vehicle-sham group; #P<0.05 vs. corresponding vehicle-I/R mice.
Panels C: Nitrotyrosine modification of protein, a marker for nitrative stress, increases with
time following I/R injury, and CBD pretreatment at 10 mg/kg attenuates these increases at
all time points of reperfusion studied (2, 6 and 24 hours).
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Results are mean±SEM for both panels and n=8–12/group. *P<0.05 vs. vehicle; #P<0.05 vs.
corresponding vehicle-I/R mice.
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Figure 11. Cannabidiol attenuates I/R-induced hepatic nitrotyrosine staining
Panel A: Increased nitrotyrosine staining after 6 hours of liver reperfusion in perivascular
area (endothelial cells and surrounding layers of hepatocytes), which was attenuated by
CBD treatment (200x magnification). Similar pattern, but weaker staining was seen at 2
hours of reperfusion (not shown).
Panel B: Very strong hepatic nitrotyrosine staining in perivascular area at 24 hours of
reperfusion (200x magnification). On the magnified insert (middle image) it is clearly shown
that the strong nitrotyrosine staining was present in hepatocytes around the vessels,
endothelial cells, and in inflammatory infiltrate (neutrophil granulocytes, macrophages,
etc.). CBD was able to attenuate the I/R-induced nitrotyrosine formation.
Panel C shows further details of nitrotyrosine staining after 24 hours of reperfusion with a
1000x magnification in endothelial cells, hepatocytes and in the inflammatory infiltrate.
Similar staining was seen in 4 to 6 livers/group.
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Figure 12. Cannabidiol attenuates LPS-induced NF-κB activation and TNFα secretion in
Kupffer cells
Panel A: Western blot analysis demonstrates inhibition of nuclear transcription factor NF-κB
(IκB) expression and its phosphorylation in the cytosolic fraction. CBD attenuates LPS
induced phosphorylation of IκB in Kupffer cells. β-Actin is used as loading control.
Panel B: CBD (0.3–3 μM) attenuates LPS induced TNFα secretion of Kupffer cells in dose-
dependent manner. Results are mean±SEM of n=4–6/group. *P<0.05 vs. vehicle; #P<0.05
vs. LPS.
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Figure 13. Cannabidiol attenuates the TNF-α induced adhesion molecules expression in human
liver sinusoidal endothelial cells (HLSEC)
Treatment of HLSEC cells with TNF-α for 6 hrs markedly enhances the expression of
adhesion molecules such as ICAM-1 and VCAM-1. CBD (1 μM) attenuates this enhanced
expression of adhesion molecules ICAM-1 (Panel A) and VCAM-1 (Panel B). Cannabinoid
receptors antagonists/inverse agonists such as SR141716 (SR1 for CB1 receptor) and
SR144528 (SR2 for CB2 receptor) at 1 μM could not prevent the CBD-mediated attenuation
of TNF-α-induced adhesion molecules expression. Results are mean±SEM of n=4–6/group.
*P<0.05 vs. vehicle; #P<0.05 vs. TNF-α.
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Figure 14. Cannabidiol attenuates the TNF-α induced polymorphonuclear cells (PMN) adhesion
to human liver sinusoidal endothelial cells (HLSEC)
Representative images and quantification of human neutrophil adhesion to activated human
liver endothelial cells. Treatment of HLSEC cells with TNF-α (50 ng/ml) for 6 hrs markedly
enhances PMN adhesion. CBD (1 μM) attenuates this enhanced PMN adhesion.
Cannabinoid receptors antagonists/inverse agonists such as SR141716 (SR1 for CB1
receptor) and SR144528 (SR2 for CB2 receptor) at 1 μM could not prevent the CBD-
mediated attenuation of TNF-α-induced PMN adhesion. Results are mean±SEM of n=4–6/
group. *P<0.05 vs. vehicle; #P<0.05 vs. TNF-α.
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